Scientists have created the first viable alternative to antibiotics, marking the next step in the fight against drug-resistant superbugs Scientists have created the first viable alternative to antibiotics, marking the next step in the fight against drug-resistant superbugs. A small test study has found the new drug is effective at targeting the bacteria that causes MRSA. Researchers believe the likelihood of the bug developing a resistance to the new drug is 'very limited'. A version of the drug is already used in specialist creams to treat conditions including acne, eczema, rosacea and skin irritations. Dutch biotech firm Micreos claims Staphefekt is the first endolysin - a bacteria-killing enzyme - available for use on human skin.
@highlight
A small test study found Staphefekt is effective in targeting MRSA
@highlight
Scientists believe likelihood  the bug will become resistant to the new drug is 'very limited', prompting them to hail the discovery a breakthrough
@highlight
Drug is already used in creams to combat skin conditions including eczema
@highlight
Targets bacteria resistant to antibiotics but leaves 'good' strains alone
@highlight
Britain's chief medical officer has said the threat posed by antibiotic resistant strains of bacteria is 'as bad as terrorism'
Staphefekt
Staphefekt
The firm is to conduct clinical trials of @placeholder and is looking to expand them internationally.